Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Jiangsu Nhwa Pharmaceutical Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Jiangsu Nhwa Pharmaceutical has been growing earnings at an average annual rate of 11.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7% per year. Jiangsu Nhwa Pharmaceutical's return on equity is 16.6%, and it has net margins of 20.7%.
Anahtar bilgiler
11.9%
Kazanç büyüme oranı
11.7%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 10.9% |
| Gelir büyüme oranı | 7.0% |
| Özkaynak getirisi | 16.6% |
| Net Marj | 20.7% |
| Sonraki Kazanç Güncellemesi | 26 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has A Rock Solid Balance Sheet
Sep 20
The Market Doesn't Like What It Sees From Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings Yet
Sep 04Here's Why Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has Caught The Eye Of Investors
Jul 22Jiangsu Nhwa Pharmaceutical (SZSE:002262) Seems To Use Debt Rather Sparingly
Jun 16Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Share Price Is Matching Sentiment Around Its Earnings
May 09Jiangsu Nhwa Pharmaceutical (SZSE:002262) Ticks All The Boxes When It Comes To Earnings Growth
Apr 18Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Apr 02Gelir ve Gider Dağılımı
Jiangsu Nhwa Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 5,405 | 1,121 | 2,027 | 613 |
| 31 Mar 24 | 5,220 | 1,075 | 1,979 | 583 |
| 31 Dec 23 | 5,042 | 1,037 | 1,959 | 549 |
| 30 Sep 23 | 4,834 | 1,044 | 1,885 | 548 |
| 30 Jun 23 | 4,698 | 998 | 1,943 | 501 |
| 31 Mar 23 | 4,485 | 939 | 1,910 | 463 |
| 01 Jan 23 | 4,299 | 901 | 1,849 | 454 |
| 30 Sep 22 | 4,164 | 867 | 1,847 | 408 |
| 30 Jun 22 | 4,072 | 834 | 1,810 | 387 |
| 31 Mar 22 | 4,024 | 819 | 1,743 | 385 |
| 01 Jan 22 | 3,936 | 798 | 1,750 | 352 |
| 30 Sep 21 | 3,879 | 830 | 1,638 | 308 |
| 30 Jun 21 | 3,744 | 787 | 1,587 | 301 |
| 31 Mar 21 | 3,528 | 759 | 1,516 | 277 |
| 31 Dec 20 | 3,361 | 729 | 1,445 | 246 |
| 30 Sep 20 | 3,326 | 714 | 1,435 | 236 |
| 30 Jun 20 | 3,534 | 694 | 1,498 | 214 |
| 31 Mar 20 | 3,837 | 675 | 1,622 | 185 |
| 31 Dec 19 | 4,149 | 663 | 1,664 | 189 |
| 30 Sep 19 | 4,167 | 623 | 1,608 | 182 |
| 30 Jun 19 | 4,090 | 585 | 1,512 | 181 |
| 31 Mar 19 | 3,981 | 549 | 1,421 | 178 |
| 31 Dec 18 | 3,858 | 525 | 1,350 | 172 |
| 30 Sep 18 | 3,764 | 472 | 1,173 | 149 |
| 30 Jun 18 | 3,581 | 447 | 1,077 | 179 |
| 31 Mar 18 | 3,482 | 411 | 1,082 | 146 |
| 31 Dec 17 | 3,394 | 395 | 1,066 | 111 |
| 30 Sep 17 | 3,274 | 400 | 1,121 | 79 |
| 30 Jun 17 | 3,181 | 347 | 1,164 | 0 |
| 31 Mar 17 | 3,097 | 325 | 1,085 | 0 |
| 31 Dec 16 | 3,018 | 310 | 1,005 | 0 |
| 30 Sep 16 | 3,004 | 297 | 963 | 0 |
| 30 Jun 16 | 2,937 | 284 | 880 | 0 |
| 31 Mar 16 | 2,851 | 269 | 856 | 0 |
| 31 Dec 15 | 2,767 | 258 | 817 | 0 |
| 30 Sep 15 | 2,694 | 257 | 760 | 0 |
| 30 Jun 15 | 2,628 | 246 | 745 | 0 |
| 31 Mar 15 | 2,566 | 235 | 718 | 0 |
| 31 Dec 14 | 2,501 | 223 | 692 | 0 |
| 30 Sep 14 | 2,418 | 213 | 676 | 0 |
| 30 Jun 14 | 2,375 | 201 | 675 | 0 |
| 31 Mar 14 | 2,310 | 186 | 677 | 0 |
| 31 Dec 13 | 2,236 | 176 | 659 | 0 |
Kaliteli Kazançlar: 002262 yüksek kaliteli kazançlara sahip.
Büyüyen Kar Marjı: 002262 şirketinin mevcut net kar marjları (20.6%) geçen yıla göre daha düşük (20.9%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 002262 şirketinin kazancı son 5 yılda yılda 12.1% arttı.
Büyüme Hızlandırma: 002262 şirketinin geçen yılki kazanç artışı ( 14.4% ), 5 yıllık ortalamasını ( 12.1% aştı ).
Kazançlar vs. Sektör: 002262 earnings growth over the past year (12.3%) exceeded the Pharmaceuticals industry -0.6%.
Özkaynak Getirisi
Yüksek ROE: 002262's Return on Equity (16.6%) is considered low.